undefined undefined
NaN.000
NaN.00%
4D Molecular Therapeutics press release (NASDAQ:FDMT): Q1 net loss was $32.4 million. Cash and cash equivalents and marketable securities were $589 million as of March 31, 2024. Research and developme...
05-10 05:49
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.78) by 15.38 percent.
05-10 05:16
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 华创医药 2024/5/8 年龄相关性黄斑变性(Age-Relate...
05-09 08:00
加拿大皇家银行:维持4D Molecular Therapeutics(FDMT.US)评级,由优于大市调整至优于大市评级, 目标价由35.00美元调整至40...
04-16 01:22
Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling advancement into
03-01 05:35
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiopulmonary exercise testing) and/or cardiac quality of life (KCCQ) in all
02-12 21:10
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through...
02-12 21:00
Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction.
02-09 03:59
4D Molecular Therapeutics shares are trading lower by 12.7% Wednesday afternoon. The company announced pricing of an upsized underwritten public offering.
02-08 03:56
Goldman Sachs analyst Salveen Richter reinstates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and announces $81 price target.
02-07 20:17